IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Clinical trial NCT05359445 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05359445
- Sponsor
- Immatics Biotechnologies GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-19
- Primary completion
- 2026-03-18
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.